Physicians' prescribing preferences were a potential instrument for patients' actual prescriptions of antidepressants

Journal of Clinical Epidemiology

Volumn 66, Issue 12, 2013, Pages 1386-1396

  Davies, Neil M ^a   Gunnell, David ^a   Thomas, Kyla H ^a   Metcalfe, Chris ^a   Windmeijer, Frank ^a   Martin, Richard M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Causality; Clinical Practice Research Datalink (CPRD); Confounding by indication; Instrumental variables; Physicians' prescribing preferences; Translational epidemiology

Indexed keywords

PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; AUTOMUTILATION; CORRELATION ANALYSIS; DRUG CHOICE; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; SUICIDE; UNITED KINGDOM;

EID: 84886946377     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2013.06.008     Document Type: Article

References (61)

1. M.A. Hernán Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology Am J Epidemiol 155 2002 176 184
2. A. Walker Confounding by indication Epidemiology 7 1996 335 336
3. A.D. McMahon Approaches to combat with confounding by indication in observational studies of intended drug effects Pharmacoepidemiol Drug Saf 12 7 2003 551 558
4. Pearl J. Why there is no statistical test for confounding, why many think there is, and why they are almost right. UCLA Computer Science Department, Technical Report R-256, TECHNICAL REPORT R-256, January 1998, Available at: http://ftp.cs.ucla.edu/pub/stat-ser/R256.pdf.
5. D.A. Lawlor, G. Davey Smith, D. Kundu, K.R. Bruckdorfer, and S. Ebrahim Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence? Lancet 363 2004 1724 1727
6. D. Lawlor, and G. Davey Smith Commentary: the hormone replacement-coronary heart disease conundrum: is this the death of observational epidemiology? Int J Epidemiol 33 2004 464 467
7. Collet J-P, Boivin J-F. Bias and confounding in pharmacoepidemiology. In: Strom BL, ed. Pharmacoepidemiology. Chichester, UK: John Wiley & Sons, Ltd; 2006: pp 765-784.
8. H. Tamim, A.A. Monfared, and J. LeLorier Application of lag-time into exposure definitions to control for protopathic bias Pharmacoepidemiol Drug Saf 16 3 2007 250 258
9. J.D. Angrist, and J.S. Pischke Mostly harmless econometrics: an empiricist's companion 2009 Princeton University Press Princeton, NJ
10. W. Greene Econometric analysis 2003 Prentice Hall Upper Saddle River, NJ
11. J. Wooldridge Econometric analysis of cross section and panel data 2002 The MIT press Cambridge, Massachusetts
12. J.D. Angrist, and G.W. Imbens Two-stage least squares estimation of average causal effects in models with variable treatment intensity J Am Stat Assoc 90 1995 431 442
13. J.D. Angrist, G.W. Imbens, and D.B. Rubin Identification of causal effects using instrumental variables J Am Stat Assoc 91 1996 444 455
14. J.J. Heckman, and E.J. Vytlacil Local instrumental variables and latent variable models for identifying and bounding treatment effects Proc Natl Acad Sci U S A 96 1999 4730 4734
15. M.A. Hernán, and J. Robins Instruments for causal inference: an epidemiologist's dream? Epidemiology 17 2006 360 372
16. S. Greenland An introduction to instrumental variables for epidemiologists Int J Epidemiol 29 2000 722 729
17. M.A. Brookhart, P.S. Wang, D.H. Solomon, and S. Schneeweiss Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable Epidemiology 17 2006 268 275
18. C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, and B. Davis Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis N Engl J Med 343 2000 1520 1528
19. F. Silverstein, G. Faich, J. Goldstein, L. Simon, T. Pincus, and A. Whelton Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial JAMA 284 2000 1247 1255
20. S. Trelle, S. Reichenbach, S. Wandel, P. Hildebrand, B. Tschannen, and P.M. Villiger Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis BMJ 342 2011 c7086
21. P. Jüni, L. Nartey, S. Reichenbach, R. Sterchi, P. Dieppe, and M. Egger Risk of cardiovascular events and rofecoxib: cumulative meta-analysis Lancet 364 2004 2021 2029
22. J.A. Rassen, M.A. Brookhart, R. Glynn, M. Mittleman, and S. Schneeweiss Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships J Clin Epidemiol 62 2009 1226 1232
23. J.A. Rassen, M.A. Brookhart, R. Glynn, M. Mittleman, and S. Schneeweiss Instrumental variables II: instrumental variable application-in 25 variations, the physician prescribing preference generally was strong and reduced covariate imbalance J Clin Epidemiol 62 2009 1233 1241
24. M.A. Brookhart, and S. Schneeweiss Preference-based instrumental variable methods for the estimation of treatment effects: assessing validity and interpreting results Int J Biostat 3 1 2007 14
25. S. Schneeweiss, S. Setoguchi, M.A. Brookhart, C. Dormuth, and P.S. Wang Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients Can Med Assoc J 176 5 2007 627 632
26. S. Schneeweiss, J.D. Seeger, J. Landon, and A.M. Walker Aprotinin during coronary-artery bypass grafting and risk of death N Engl J Med 358 2008 771 783
27. P.S. Wang, S. Schneeweiss, J. Avorn, M. Fischer, H. Mogun, and D.H. Solomon Risk of death in elderly users of conventional vs. atypical antipsychotic medications N Engl J Med 353 2005 2335 2341
28. N.M. Davies, G. Davey Smith, F. Windmeijer, and R.M. Martin COX-2 selective nonsteroidal anti-inflammatory drugs and risk of gastrointestinal tract complications and myocardial infarction: an instrumental variable analysis Epidemiology 24 2013 352 362
29. N.M. Davies, G. Davey Smith, F. Windmeijer, and R.M. Martin Issues in the reporting and conduct of instrumental variable studies: a systematic review Epidemiology 24 2013 May 363 369
30. D. Fergusson Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials BMJ 330 2005 396
31. D.J. Safer, and J.M. Zito Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents J Child Adolesc Psychopharmacol 16 1-2 2006 159 169
32. C. Martinez, S. Rietbrock, L. Wise, D. Ashby, J. Chick, and J. Moseley Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study BMJ 330 2005 389 393
33. D. Gunnell, J. Saperia, and D. Ashby Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review BMJ 330 2005 385 388
34. Clinical Practice Research Datalink - CPRD [Internet]. Available at http://www.cprd.com/intro.asp. Accessed October 1, 2012.
35. Great Britain Key health statistics from general practice 1998: analyses of morbidity and treatment data, including time trends, England and Wales 2000 Office for National Statistics London, UK
36. E. Herrett, S. Thomas, W. Schoonen, L. Smeeth, and A. Hall Validation and validity of diagnoses in the General Practice Research Database: a systematic review Br J Clin Pharmacol 69 1 2010 4 14
37. N. Khan, S. Harrison, and P. Rose Validity of diagnostic coding within the General Practice Research Database: a systematic review Br J Gen Pract 60 572 2010 e128 e136
38. L.A. García Rodríguez, and S. Pérez Gutthann Use of the UK General Practice Research Database for pharmacoepidemiology Br J Clin Pharmacol 45 5 1998 419 425
39. S.S. Jick, J.A. Kaye, C. Vasilakis-Scaramozza, L.A. Garcia Rodríguez, A. Ruigómez, and C.R. Meier Validity of the general practice research database Pharmacotherapy 23 5 2003 686 689
40. H. Jick, B. Terris, L. Derby, and S. Jick Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom Pharmacoepidemiol Drug Saf 1 6 1992 347 349
41. H. Jick, S.S. Jick, and L.E. Derby Validation of information recorded on general practitioner based computerised data resource in the United Kingdom BMJ 302 1991 766 768
42. N. Middleton, D. Gunnell, E. Whitley, D. Dorling, and S. Frankel Secular trends in antidepressant prescribing in the UK, 1975-1998 J Public Health Med 23 4 2001 262 267
43. S. Burgess, and S.G. Thompson Bias in causal estimates from Mendelian randomization studies with weak instruments Stat Med 30 2011 1312 1323
44. S. Burgess, and S.G. Thompson Avoiding bias from weak instruments in Mendelian randomization studies Int J Epidemiol 40 2011 755 764
45. M. Bun, and M. De Haan Weak instruments and the first stage F statistic in IV models with a nonscalar error covariance structure 2010 University of Amsterdam, Working Paper /2 Available at: http://aseri.uva.nl/binaries/content/ assets/subsites/amsterdam-school-of-economics-research-institute/ uva-econometrics/dp-2010/1002.pdf
46. K. Hawton, and K. Van Heeringen Suicide Lancet 373 2009 1372 1381
47. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 5 1987 373 383
48. J. Stock, and M. Yogo Testing for weak instruments in linear IV regression 2002 National Bureau of Economic Research Technical Working Paper Series Cambridge, MA No. 284. Available at http://www.nber.org/papers/t0284.pdf Accessed April 1, 2010.
49. H. White A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity Econometrica 48 4 1980 817 838
50. P.C. Mahalanobis On the generalized distance in statistics Proc Natl Inst Sci India 2 1 1936 49 55
51. T.S. Breusch, and A.R. Pagan The Lagrange multiplier test and its applications to model specification in econometrics Rev Econ Stud 1980 239 253
52. K.H. Thomas, N. Davies, C. Metcalfe, F. Windmeijer, R.M. Martin, and D. Gunnell Validation of suicide and self-harm records in the Clinical Practice Research Datalink Br J Clin Pharmacol 76 2013 145 157
53. D.-M. Wu Alternative tests of independence between stochastic regressors and disturbances Econometrica 41 4 1973 733 750
54. J.A. Hausman Specification tests in econometrics Econometrica 46 6 1978 1251 1271
55. Baum C, Schaffer M, Stillman S. IVREG2: Stata module for extended instrumental variables/2SLS and GMM estimation. Stat Softw Components. Available at: http://EconPapers.repec.org/RePEc:boc:bocode:s425401.
56. Schaffer ME. XTIVREG2: Stata module to perform extended IV/2SLS, GMM and AC/HAC, LIML and k-class regression for panel data models [Internet]. 2005. Available at http://ideas.repec.org/c/boc/bocode/s456501.html. Accessed January 10, 2013.
57. Leuven E, Sianesi B. PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. Stat Softw Components [Internet]. 2012. Available at http://ideas.repec.org/c/boc/bocode/s432001.html. Accessed May 13, 2013.
58. R.M. Martin, M. May, and D. Gunnell Did intense adverse media publicity impact on prescribing of paroxetine and the notification of suspected adverse drug reactions? Analysis of routine databases, 2001-2004 Br J Clin Pharmacol 61 2 2006 224 228
59. A.P. Dawid Causal inference without counterfactuals J Am Stat Assoc 95 2000 407 424
60. S. Hennessy, C. Leonard, C. Palumbo, X. Shi, and T. Ten Have Instantaneous preference was a stronger instrumental variable than 3-and 6-month prescribing preference for NSAIDs J Clin Epidemiol 61 2008 1285 1288
61. R. Ionescu-Ittu, M. Abrahamowicz, and L. Pilote Treatment effect estimates varied depending on the definition of the provider prescribing preference-based instrumental variables J Clin Epidemiol 65 2012 155 162